ImmunOs Therapeutics AG Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023. Excellent presentation team! Osiris Marroquin Belaunzaran Anahita Rafiei, PhD Discover more here_ https://lnkd.in/eCBzQtiC #immunotherapy #cancer #oncology #esmo #bispecifics #cancertherapy #antitumor #HLA #multitarget #multimodal #immunooncology
ImmunOs Therapeutics AG
Biotechnologie
Schlieren, Zurich 5.197 Follower:innen
Novel human immunomodulatory proteins for cancer and autoimmune diseases with a specific role in innate immunity
Info
ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).
- Website
-
http://www.immunostherapeutics.com
Externer Link zu ImmunOs Therapeutics AG
- Branche
- Biotechnologie
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Schlieren, Zurich
- Art
- Privatunternehmen
- Gegründet
- 2014
- Spezialgebiete
- Immuno-Oncology, Oncology, Biotech, Pharmaceuticals, Global, Research and Development, Immunology, Clinical Research, Business Development, Sales and Marketing und Leadership
Orte
-
Primär
Wegbeschreibung
Wagistrasse 18
Schlieren, Zurich 8952, CH
Beschäftigte von ImmunOs Therapeutics AG
Updates
-
Our team presented an Overview of Phase 1a/b Trial of our Lead Compound IOS-1002 at ESMO 2023. We are very happy with the progress that the Clinical Trial is having and we would love to share more exciting news about it soon! Discover more about the Presentation at ESMO 2023 here: https://lnkd.in/erw5j8UV #ESMO2023 #ESMO #ESMODailyReporter #ESMO23 #immunotherapy #cancer #oncology #clinicaltrial
-
-
Wonderful news! ImmunOs Therapeutics AG Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA. Congratulations to our amazing team! 👏 Read more here: https://lnkd.in/eFu468rQ #immunology #oncology #cancer #clinicaltrials #immunotherapy #solidtumors #keytruda #collaboration
-
-
Fantastic presentation at Festival of Biologics, congratulations Hilmar Ebersbach ! 👏 #festivalofbiologics
Excellent presentation from Hilmar Ebersbach (ImmunOs Therapeutics AG) ‘IOS-1002-A novel multi target therapeutic modulating 3 checkpoint pathways to activate both adaptive and innate immunity’ #festivalofbiologics #standingroomonly
-
-
We are delighted to announce that Dr. Constanze Guenther has joined ImmunOs Therapeutics as Senior Vice President, CMC and Technical Development. Welcome to the team! https://lnkd.in/e8ahS6mS #immunotherapy #cancerimmunotherapy #cmc #manufacturing #management #HLAbased #oncology
-